|Systematic (IUPAC) name|
|Molar mass||382.43 g/mol|
ADB-FUBINACA is a designer drug identified in synthetic cannabis blends in Japan in 2013. The (S) enantiomer of ADB-FUBINACA is claimed in Pfizer patent WO 2009/106982 and has been reported to be a potent agonist of the CB1 receptor and CB2 receptor with an EC50 value of 1.2 nM and 3.5 nM respectively. ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135. ADB-FUBINACA appears to be the product of rational drug design, since it differs from AB-FUBINACA only by the replacement of the isopropyl group with a tert-butyl group.
An analogue of ADB-FUBINACA, ADSB-FUB-187, containing a more functionalized carboxamide substituent was recently reported.
- Uchiyama, N.; Matsuda, S.; Kawamura, M.; Kikura-Hanajiri, R.; Goda, Y. (2013). "Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal products". Forensic Toxicology 31: 223–240. doi:10.1007/s11419-013-0182-9.
- Samuel D Banister, Michael Moir, Jordyn Stuart, Richard C Kevin, Katie E Wood, Mitchell Longworth, Shane M Wilkinson, Corinne Beinat, Alxendra S Buchanan, Michelle Glass, Mark Connor, Iain S McGregor, Michael Kassiou (July 2015). "The pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA and 5F-ADBICA". ACS Chemical Neuroscience 6: 1546–59. doi:10.1021/acschemneuro.5b00112. PMID 26134475.
- Buchler IP et al, INDAZOLE DERIVATIVES. WO 2009/106982
- Kevin G. Shanks, William Clark, George Behonick (January 2016). "Death Associated With the Use of the Synthetic Cannabinoid ADB-FUBINACA". Journal of Analytical Toxicology. doi:10.1093/jat/bkv142. PMID 26755539.
|This cannabinoid related article is a stub. You can help Wikipedia by expanding it.|